PET-CT Predicts Favorable Breast Cancer Outcomes Early

PET-CT measures glucose use numerically as an indicator of cancer cell metabolism. These values, called SUV (specific uptake value), are useful prognostic factors in various cancers. Identifying poor outcomes early affects patient management and can help detect and treat recurrence. Researchers from South Korea's Yonsei University published an important article online in July 2016 in the Journal of Nuclear Medicine, a leading medical imaging journal. The distinguished nuclear medicine specialist Prof. Dr. Akın Yıldızinterpreted this study for you.
The study examined PET-CT's value in predicting poor outcomes through response to preoperative tumor-shrinking (neoadjuvant) chemotherapy in locally advanced breast cancer. In 87 patients, cancer tissue metabolism was assessed by SUV after 3 cycles. Patients subsequently underwent surgery and were grouped by pathological response. Remaining cancer tissue after chemotherapy was calculated to estimate response, categorized as RCB-0 (no residual disease), RCB-1 (mild), RCB-2 (moderate) or RCB-3 (substantial residual disease). Statistical analysis found a significant negative relationship between SUV reduction and remaining tumor amount (RCB category) (R = -0,408; p <0.001). Multivariable analysis found the pretreatment-to-post-treatment SUV change an important predictor of recurrence-free and overall survival. When patients were grouped by pathological response, recurrence and survival differed significantly between those with cell activity above % 66.4 and those below it.
In conclusion, this study showed that PET-CT after 3 treatment cycles in locally advanced breast cancer predicts favorable outcomes early, independently of pathological response. Interim PET-CT therefore not only shows response, but informs later follow-up, planning and possible adverse outcomes.
Sources
The Prognostic Impact of Early Change in Standardized Uptake Value of 18F-fluorodeoxy-glucose Positron Emission Tomography after Neoadjuvant
Chemotherapy in Locally Advanced Breast Cancer Patients.
J Nucl Med. 2016 Mar 31. pii: jnumed.115.166322.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.